Multikine
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
Multikine is an investigational immunomodulator composed of a proprietary cocktail of naturally occurring cytokines such as interleukins, interferons, chemokines, and colony-stimulating factors. The therapy is administered prior to front-line surgery or radiotherapy. It is designed to activate anti-tumor immune responses and to increase tumor susceptibility to radiotherapy and chemotherapy.
TABLE OF CONTENTS
4 Product Profiles
4 Multikine : Head and neck cancer
LIST OF FIGURES
9 Figure 1: Multikine for head and neck cancer – SWOT analysis
10 Figure 2: Datamonitor Healthcare’s drug assessment summary of Multikine for SCCHN
11 Figure 3: Datamonitor Healthcare’s drug assessment summary of Multikine for SCCHN
13 Figure 4: Multikine sales for SCCHN across the US, Japan, and five major EU markets, by country, 2017–26
LIST OF TABLES
5 Table 1: Multikine drug profile
6 Table 2: Multikine Phase III trials in head and neck cancer
8 Table 3: Multikine early-phase data in head and neck cancer
14 Table 4: Multikine sales for SCCHN across the US, Japan, and five major EU markets, by country ($m), 2017–26
16 Table 5: Multikine patient numbers for SCCHN across the US, Japan, and five major EU markets, by country, 2017–26
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
GSK Woes Raise Big Pharma R&D Question 
Sign up to the